RBC Capital raised the firm’s price target on Boston Scientific to $61 from $58 and keeps an Outperform rating on the shares. The company’s Investor Day laid out its financial and strategic roadmap while setting bullish 2024-26 targets calling for 8%-10% organic revenue and double-digit EPS growth, the analyst tells investors in a research note. Boston Scientific remains one of RBC’s Top 30 Global Ideas, and there is room for upward estimate revision during the long-range plan timeframe, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BSX:
- CVS Health appoints Boston Scientific CEO Michael Mahoney to board
- Boston Scientific price target raised to $63 from $60 at Baird
- Boston Scientific price target raised to $60 from $56 at Mizuho
- Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.
- Boston Scientific signs agreement to acquire Relievant Medsystems